Study on the Incidence of Intussusception (IS) in Children Aged < 12 Months in Japan
NCT01479491 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 54
Last updated 2012-10-22
Summary
This study aims to analyse baseline data on IS in order to monitor the possibility of increased risk of IS in children aged \<12 months after introduction of the Rotarix vaccination in Japan.
Conditions
- Intussusception
Interventions
- OTHER
-
Data collection
Data source will be the Japan Medical Data Centre Company Limited (JMDC) - JMDC Medical Data Bank (JMDC-MDB) database. Aggregated data (age in months and years and gender) for all subjects recorded in the database and subject-level data for IS cases will be extracted from the database. This database will be reviewed to extract data for the period between January 2005 and April 2011. Cases of IS will be identified using the International Classification of Diseases-10 (ICD-10) diagnostic codes, examination codes and procedural codes.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
GSK Clinical Trials · GlaxoSmithKline
Eligibility
- Max Age
- 12 Months
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-11-30
- Primary Completion
- 2011-11-30
- Completion
- 2011-11-30
More Related Trials
-
Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries
NCT01047839 ·Status: COMPLETED ·Phase: PHASE3
-
To Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK's Oral Human Rotavirus Vaccine in Pre-Term Infants
NCT00420745 ·Status: COMPLETED ·Phase: PHASE3
-
Study of a Birth Dose of GlaxoSmithKline Biologicals' 251154 Vaccine
NCT01110044 ·Status: WITHDRAWN ·Phase: PHASE2
-
Serologic Response to Porcine Circovirus Type 1 (PCV-1) in Infants Following Administration of Rotarix™
NCT02153333 ·Status: COMPLETED
-
Phase III Study of Intramuscular TAK-816 in Healthy Infants
NCT02074345 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity Study of the Japanese Encephalitis Vaccine IC51
NCT00604708 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants
NCT00197210 ·Status: COMPLETED ·Phase: PHASE3
-
Study of TAK-816 in Healthy Infants
NCT01379846 ·Status: COMPLETED ·Phase: PHASE3
-
Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51
NCT00595790 ·Status: COMPLETED ·Phase: PHASE3
-
Burden of Invasive Group B Streptococcal (GBS) Disease in Young Infants in China
NCT01933646 ·Status: COMPLETED
-
A Study to Test 2 Doses of the HRV Vaccine in Healthy Infants.
NCT00140673 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Tolerability of the Japanese Encephalitis Vaccine IC51
NCT00605085 ·Status: COMPLETED ·Phase: PHASE3
-
Assess the Immunogenicity & Safety of 2 Doses of Oral Live Attenuated Human Rota(HRV)Vaccine in Healthy Infants in India
NCT00289172 ·Status: COMPLETED ·Phase: PHASE3
-
To Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants in Co-administration With Specific Childhood Vaccines
NCT00140686 ·Status: COMPLETED ·Phase: PHASE3
-
Vaccine Efficacy Against Rotavirus Diarrhea; Vaccine Given With Routine Childhood Vaccinations in Healthy African Infants
NCT00241644 ·Status: COMPLETED ·Phase: PHASE3
-
Effectiveness Study of GSK Biologicals' Rotarix TM Vaccine in Hospitalized Children
NCT01177826 ·Status: COMPLETED
-
Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.
NCT01198769 ·Status: COMPLETED ·Phase: PHASE4
-
Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated Toddlers
NCT01323647 ·Status: COMPLETED ·Phase: PHASE3
-
Assessment of Clinical Consistency of Three Production Lots of GSK Biologicals' HRV Vaccine
NCT00757770 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants
NCT00937404 ·Status: COMPLETED ·Phase: PHASE1
-
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vaccine
NCT01021293 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-detoxified Pertussis Toxin in Young Adults Previously Primed With Acellular Pertussis Vaccines
NCT05193734 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers
NCT00920439 ·Status: COMPLETED ·Phase: PHASE3
-
Follow-up Study on the Antibody Response to Hepatitis B, Acellular Pertussis Toxin and Inactivated Poliovirus Antigens 1 Month After the 4th Hexavac® Vaccination in Healthy Children, Who Participated in NeisVac-C Study 216
NCT00161941 ·Status: COMPLETED
-
Assessing Contacts' Decision Making on Reducing the Risk of Pertussis Transmission to Newborns Through Immunisation
NCT01890447 ·Status: COMPLETED